Why the study?
Does the p38 MAPK inhibitor VX-702 affect platelet aggregation in normal individuals?
Population
Platelets from normal individuals
Comparison
Pre-treatment with 1 microM VX-702 vs Absence of VX-702 / Aspirin
Design
Preclinical
Authors
Loading...
May avoid bleeding risk unlike aspirin; hypothesis-generating for p38 MAPK inhibition in thrombosis.
Does the p38 MAPK inhibitor VX-702 affect platelet aggregation in normal individuals?
Unlike aspirin, the p38 MAPK inhibitor VX-702 does not affect platelet aggregation, suggesting it would not increase bleeding risk in treated patients.
Kuliopulos et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: